Structure-activity relationship of linear peptide Bu-His6-DPhe7-Arg8-Trp9-Gly 10-NH2 at the human melanocortin-1 and -4 receptors: DPhe7 and Trp9 substitution

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 4, 2003, Pages 649-652

  Danho, Waleed ^a   Swistok, Joseph ^a   Cheung, Adrian Wai Hing ^a   Kurylko, Grazyna ^a   Franco, Lucia ^a   Chu, Xin Jie ^a   Chen, Li ^a   Yagaloff, Keith ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; BETA INTERMEDIN[11-22][11 (N ACETYLCYSTEINE) 14 (3,4 DICHLORO DEXTRO PHENYLALANINE) 18 CYSTEINE 22 ASPARTIC ACID AMIDE] 11,18 CYCLIC DISULFIDE; HS 024; MBP 10; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 4 RECEPTOR; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; PENTAPEPTIDE; RECEPTOR BLOCKING AGENT; SHU 9203; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; DRUG POTENCY; EMBRYO; HUMAN; HUMAN CELL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRUCTURE ACTIVITY RELATION;

EID: 0037294189     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)01052-1     Document Type: Article

References (27)

1. Cone R.D. The Melanocortin Receptors. 2000;Humana, Totowa.
2. MacNeil D.J., Howard A.D., Guan X., Fong T.M., Nargund R.P., Bednarek M.A., Goulet M.T., Weinberg D.H., Strack A.M., Marsh D.J., Chen H.Y., Shen C-P., Chen A.S., Rosenblum C.I., MacNeil T., Tota M., MacIntyre E.D., Van der Ploeg L.H.T. Eur. J. Pharmacol. 440:2002;141.
3. Cheung A.W.-H., Danho W., Swistok J., Qi L., Kurylko G., Franco L., Yagaloff K., Chen L. Bioorg. Med. Chem. Lett. 12:2002;2407.
4. Cheung, A. W.-H.; Danho, W.; Swistok, J.; Qi, L.; Kurylko, G.; Rowan, K.; Yeon, M.; Franco, L.; Chu, X.-J.; Chen, L.; Yagaloff, K. Bioorg. Med. Chem. Lett. 2003, 13, 133.
5. Holder J.R., Bauzo R.M., Xiang Z., Haskell-Luevano C. J. Med. Chem. 45:2002;3073.
6. (a). For earlier works on DPhe substitution in α-MSH derivatives, see: Hruby V.J., Wilkes B.C., Cody W.L., Sawyer T.K., Hadley M.E. Peptide Protein Rev. 3:1984;1
7. (b) Cody W.L., Mahoney M., Knittel J.J., Hruby V.J., Castrucci A.L., Hadley M.E. J. Med. Chem. 28:1985;583
8. (c) Wilkes B.C., Cody W.L., Hruby V.J., Castrucci A.L., Hadley M.E. Int. J. Peptide Protein Res. 27:1986;685.
9. Bednarek M.A., Silva M.V., Arison B., MacNeil T., Kalyani R.N., Huang R.C., Weinberg D.H. Peptides. 20:1999;401.
10. Bednarek M.A., MacNeil T., Kalyani R.N., Tang R., Van der Ploeg L.H.T., Weinberg D.H. Biochem. Bioph. Res. Commun. 261:1999;209.
11. Bednarek M.A., MacNeil T., Kalyani R.N., Tang R., Van der Ploeg L.H.T., Weinberg D.H. J. Med. Chem. 44:2001;3665.
12. Bednarek M.A., MacNeil T., Tang R., Kalyani R.N., Van der Ploeg L.H.T., Weinberg D.H. Biochem. Bioph. Res. Commun. 286:2001;641.
13. Haskell-Luevano C., Lim S., Yuan W., Cone R.D., Hruby V.J. Peptides. 21:2000;49.
14. (a) Chen, L.; Cheung, A. W.-H.; Chu, X.-J.; Danho, W.; Swistok, J.; Yagaloff, K. A. WO 0174844, 2001; CAN 135:304143. (b) Chen, L.; Cheung, A. W.-H.; Chu, X.-J.; Danho, W.; Swistok, J.; Wang, Y.; Yagaloff, K. A. WO 0218437, 2002; CAN 136:217052.
15. (a) Chen, L.; Cheung, A. W.-H.; Chu, X.-J.; Danho, W.; Swistok, J.; Yagaloff, K. A. WO 0174844, 2001; CAN 135:304143. (b) Chen, L.; Cheung, A. W.-H.; Chu, X.-J.; Danho, W.; Swistok, J.; Wang, Y.; Yagaloff, K. A. WO 0218437, 2002; CAN 136:217052.
16. Benoit S.C., Schwartz M.W., Lachey J.L., Hagan M.M., Rushing P.A., Blake K.A., Yagaloff K.A., Kurylko G., Franco L., Danho W., Seeley R.J. J. Neurosci. 20:2000;3442.
17. Sawyer T.K., Sanfillippo P.J., Hruby V.J., Engel M.H., Heward C.B., Burnett J.B., Hadley M.E. Proc. Natl. Acad. Sci. U.S.A. 77:1980;5754.
18. Al-Obeidi F., Hadley M.E., Pettitt B.M., Hruby V.J. J. Am. Chem. Soc. 111:1989;3413.
19. Al-Obeidi F., Castrucci A.L., Hadley M.E., Hruby V.J. J. Med. Chem. 32:1989;2555.
20. Hruby V.J., Lu D., Sharma S.D., Castrucci A.L., Kesterson R.A., Al-Obeidi F., Hadley M.E., Cone R.D. J. Med. Chem. 38:1995;3454.
21. Haskell-Luevano C., Cone R.D., Monck E.K., Wan Y.-P. Biochemistry. 40:2001;6164.
22. Yang Y., Chen M., Lai Y., Gantz I., Georgeson K.E., Harmon C.M. J. Biol. Chem. 277:2002;20328.
23. (a). For examples of highly MC1R selective ligands, see: Szardenings M., Tornroth S., Mutulis F., Muceniece R., Keinanen K., Kuusinen A., Wikberg J.E.S. J. Biol. Chem. 272:1997;27943.
24. (b) Wikberg J.E.S. Eur. J. Pharmacol. 375:1999;295.
25. Kask A., Mutulis F., Muceniece R., Pahkla R., Mutule I., Wikberg J.E.S., Rago L., Schioth H.B. Endocrinology. 139:1998;5006.
26. Skuladottir G.V., Jonsson L., Skarphedinsson J.O., Mutulis F., Muceniece R., Raine A., Mutule I., Helgason J., Prusis P., Wikberg J.E.S., Schioth H.B. Br. J. Pharmacol. 126:1999;27.
27. 6 modified pentapeptides, manuscript in preparation.